Navigation Links
Treatment with anti-TNFs can increase the risk of shingles by up to 75 percent
Date:6/7/2012

Berlin, Germany, June 7 2012: Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.

"Anti-TNFs, such as infliximab, adalimumab and etanercept have become the treatment of choice for patients with inflammatory rheumatic diseases who are uncontrolled on traditional DMARDs, but it is known that a side effect of these drugs is an increased risk of bacterial infections," said Ms. Helene Che, from Lapeyronie Hospital, France and lead author of the study. "This systematic review and meta-analysis demonstrates that careful monitoring of patients treated with anti-TNFs is required for early signs and symptoms of herpes zoster and raises the issue as to when vaccination against the virus should occur."

The study authors conducted a literature search in Medline, Embase, the Cochrane library and abstracts from ACR and EULAR congresses from 2006 to 2010. From the 657 articles, 134 congress abstracts, and 11 national registries included in the literature search, 22 articles and 28 abstracts met eligibility criteria and were included in the study. The meta-analysis included a total follow up of 124,966 patient years (PY) (74,198 PY in the biologics group and 50,768 PY in the DMARD group) across five registries.

Studies were included in the meta-analysis if they reported the respective incidences of herpes infection in anti-TNF and conventional DMARD treated patients. Incidence of severe herpetic infections (multidermatomal lesions, requiring hospitalisation or intravenous treatment) were excluded and reported when available.

Herpes zoster, also known as shingles, is a painful, blistering skin rash due to the varicella-zoster virus, the same virus that causes chickenpox . People are more likely to develop it if they are older than 60, had chickenpox before the age of one and have a compromised immune system due to medications or diseasei. Symptoms include one-sided pain, tingling or burning followed by a rash of small blisters, which eventually break, ulcer and dry upi. Other symptoms may include fever, chills, abdominal pain, swollen glands, difficulty moving muscles in the face, and drooping eyelidsi. Shingles is usually treated with antiviral medications to reduce pain and complications and corticosteroids to reduce swellingi. Pain from shingles can last for months or years, even though the infection normally lasts only two to three weeks. The virus can also cause temporary or permanent paralysis.*

Abstract Number: THU0368


'/>"/>

Contact: Candice Debleu
eularpressoffice@cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
2. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
3. Hear to see: New method for the treatment of visual field defects
4. Injection of methotrexate not superior to oral therapy in juvenile arthritis treatment
5. Antioxidant shows promise as treatment for certain features of autism, Stanford study finds
6. Antiretroviral treatment for preventing HIV infection: an evidence review for physicians
7. British experts update addiction treatment guidelines
8. VCU Massey Cancer Center sees potential in novel leukemia treatment
9. Correct treatment of common diabetic foot infections can reduce amputations
10. Biomarker predicts response to cancer treatment
11. First, do no harm: Study finds danger in standard treatment for a serious lung disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of education, ... with a Microsoft Corp. employee-led hackathon team for the 2017 Microsoft One Week Hackathon ... 1’s mission overlaps seamlessly with Microsoft’s mission to empower every person and every organization ...
(Date:7/20/2017)... Falls Church, VA (PRWEB) , ... July 20, ... ... Improve Your Bottom Line, **An FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. ... a secret weapon to passing inspections and boosting quality. , It’s known as ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Business Architecture Guild® ... Knowledge (BIZBOK® Guide )v 6.0 is now available for member download. This release ... collaborative teams. , Non-members may download the Part 1 Introduction for free ...
(Date:7/20/2017)... ... July 19, 2017 , ... A local summer theatre ... funds raised to support fine arts programs in Chester County’s Elementary Schools. In ... University’s Loyd Auditorium. , More than 850 people attended the two performances, ...
(Date:7/20/2017)... ... 19, 2017 , ... Western University of Health Sciences College ... grant to train predoctoral dental students in providing care to vulnerable children ages ... , The Predoctoral Pediatric Training Project (PPTP), a five-year grant, recognizes the curriculum ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... July 10, 2017  The tenth annual BioPharm ... MA at the Sheraton Boston Hotel, September ... access to global decision makers and innovative biotech startup ... science leaders during two impactful days. BioPharm America is ... with additional networking opportunities with 4,500+ life science industry ...
(Date:7/5/2017)... of over 2,000 employees and a leader in environmental and life science testing, ... position as the top American owned and operated environmental testing firm in ... ... The ... , enhances Pace Analytical,s capability as an innovative full service provider in the ...
(Date:6/30/2017)... POINT, N.C. , June 29, 2017  Axium Pharmaceuticals Inc. ... for developing improved novel formulations and alternative dosage forms of ... ... delivery is based on our waterless self-nano emulsifying formula, which ... contact with saliva. We believe the spray will provide fast ...
Breaking Medicine Technology: